AstraZeneca’s recent acquisition of a radiopharmaceutical partner highlights the rapid growth of the radiopharmaceutical market, which is expected to reach $13.7 billion by 2032. Radiopharmaceutical therapies target cancer cells with radioactive drugs and offer potential life-saving benefits for cancer patients. Challenges in delivering radioligand therapy include the need for accurate diagnostics, short half-lives of medicines, logistical complexities, and specialized requirements for transportation and storage. As competition in the radiopharmaceutical landscape increases, companies must focus on delivery and differentiation to remain competitive. Successfully scaling up the delivery of radioligand therapy will require significant investment and effort, positioning leading companies at the forefront of this new era in healthcare.
Source link
The New Radiopharma Competition Requires Unprecedented Medical Logistics
